Migraine and Calcitonin Gene-Related Peptide Receptor Antagonist Treatment
Istanbul Aydın University Medical School, Istanbul, Turkey
Keywords: Antimigraine drug, calcitonin gene-dependent peptide, headache, migraine, receptor antagonists, treatment
Migraine is one of the primary causes of headache that reduces people's quality of life and work force, mostly affecting young and middle-aged individuals. Although many treatment options have been put forward, the treatment is still not satisfactory for many patients today. CRGP is a peptide neurotransmitter produced in numerous regions in the central nervous system. It takes part in communication between nerve cells and enables the vessels to expand, especially in areas where the need for blood increases in the brain. This vein expander triggers headaches in migraine patients, causing the body to react abnormally. Because CGRP is an important molecule for the brain to function in its normal order, there has been success in treatments done by shutting down its receptors rather than completely neutralizing them in the body. Selective CGRP receptor antagonists should be effective antimigrene drugs.
The author declared no conflicts of interest with respect to the authorship and/or publication of this article.
The author received no financial support for the research and/or authorship of this article.